title: Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group.
abstract: Epithelioid sarcoma (ES) is rare with a poor prognosis and for which a loss of INI1 expression has been recently reported. We report a study of 106 cases with clinical, histologic, and immunohistochemical data, including INI1 expression, and follow-up data. Of the 106 cases, 70 were the conventional subtype and 36 the large cell subtype. INI1 was negative in 86 cases (81.1%): 57 (81%) of 70 conventional and 29 (81%) of 36 large cell subtypes. Treatment modalities were available for 76 and follow-up for 80 patients. Of the 80 patients, 43 (54%) experienced metastasis and 25 (31%) died of the disease. Univariate analysis indicated that tumor size and mitotic index were significant for metastasis-free survival, whereas proximal location, tumor size, tumor multifocality, and mitotic index were significant for overall survival. Loss of expression of INI1 is frequent in the conventional and large cell subtypes of ES and can be used as a diagnostic marker, but it has no prognostic impact.
authors.affiliation: Department of Pathology, Institut Bergonié, Bordeaux, France.
authors.forename: Laila
authors.initials: L
authors.lastname: Chbani
authors.forename: Louis
authors.initials: L
authors.lastname: Guillou
authors.forename: Philippe
authors.initials: P
authors.lastname: Terrier
authors.forename: Anne Valérie
authors.initials: AV
authors.lastname: Decouvelaere
authors.forename: Fleur
authors.initials: F
authors.lastname: Grégoire
authors.forename: Marie José
authors.initials: MJ
authors.lastname: Terrier-Lacombe
authors.forename: Dominique
authors.initials: D
authors.lastname: Ranchère
authors.forename: Yves Marie
authors.initials: YM
authors.lastname: Robin
authors.forename: Françoise
authors.initials: F
authors.lastname: Collin
authors.forename: Paul
authors.initials: P
authors.lastname: Fréneaux
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Coindre
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D002648:Child; D002868:Chromosomal Proteins, Non-Histone / Q000032:analysis; D003131:Combined Modality Therapy; D004268:DNA-Binding Proteins / Q000032:analysis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008940:Mitotic Index; D000071796:SMARCB1 Protein; D012509:Sarcoma / Q000737:chemistry / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D012983:Soft Tissue Neoplasms / Q000737:chemistry / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D015996:Survival Rate; D014157:Transcription Factors / Q000032:analysis; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D002868:Chromosomal Proteins, Non-Histone; D004268:DNA-Binding Proteins; D000071796:SMARCB1 Protein; C513266:SMARCB1 protein, human; D014157:Transcription Factors